These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 37404252)

  • 1. Emerging Treatment Options for Myelofibrosis: Focus on Anemia.
    Sastow D; Tremblay D
    Ther Clin Risk Manag; 2023; 19():535-547. PubMed ID: 37404252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of fedratinib for the treatment of patients with primary or secondary myelofibrosis.
    Palmer J; Mesa R
    Ther Adv Hematol; 2020; 11():2040620720925201. PubMed ID: 32477483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Momelotinib versus Continued Ruxolitinib or Best Available Therapy in JAK Inhibitor-Experienced Patients with Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-2.
    Harrison CN; Vannucchi AM; Recher C; Passamonti F; Gerds AT; Hernandez-Boluda JC; Yacoub A; Sirhan S; Ellis C; Patel B; Strouse B; Platzbecker U
    Adv Ther; 2024 Sep; 41(9):3722-3735. PubMed ID: 38990433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Next Generation of JAK Inhibitors: an Update on Fedratinib, Momelotonib, and Pacritinib.
    Patel AA; Odenike O
    Curr Hematol Malig Rep; 2020 Dec; 15(6):409-418. PubMed ID: 32780250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives.
    Bose P; Verstovsek S
    Hemasphere; 2020 Aug; 4(4):e424. PubMed ID: 32903304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel therapeutics for myelofibrosis.
    Lee SE
    Blood Res; 2023 Apr; 58(S1):S13-S19. PubMed ID: 36891574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Momelotinib in myelofibrosis.
    Bruzzese A; Martino EA; Labanca C; Mendicino F; Lucia E; Olivito V; Zimbo A; Fragliasso V; Neri A; Morabito F; Vigna E; Gentile M
    Expert Opin Pharmacother; 2024 Apr; 25(5):521-528. PubMed ID: 38623844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical potential of pacritinib in the treatment of myelofibrosis.
    Duenas-Perez AB; Mead AJ
    Ther Adv Hematol; 2015 Aug; 6(4):186-201. PubMed ID: 26288713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ACVR1: A Novel Therapeutic Target to Treat Anemia in Myelofibrosis.
    Duminuco A; Chifotides HT; Giallongo S; Giallongo C; Tibullo D; Palumbo GA
    Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in potential treatment options for myeloproliferative neoplasm associated myelofibrosis.
    Bose P
    Expert Opin Orphan Drugs; 2019; 7(10):415-425. PubMed ID: 33094033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New approaches to tackle cytopenic myelofibrosis.
    Reynolds SB; Pettit K
    Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):235-244. PubMed ID: 36485113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel strategies for challenging scenarios encountered in managing myelofibrosis.
    Bose P; Mesa RA
    Leuk Lymphoma; 2022 Apr; 63(4):774-788. PubMed ID: 34775887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in pharmacotherapy for myelofibrosis: what is the current state of play?
    Tiribelli M; Morelli G; Bonifacio M
    Expert Opin Pharmacother; 2024 Apr; 25(6):743-754. PubMed ID: 38738513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anemia in myelofibrosis: Current and emerging treatment options.
    Passamonti F; Harrison CN; Mesa RA; Kiladjian JJ; Vannucchi AM; Verstovsek S
    Crit Rev Oncol Hematol; 2022 Dec; 180():103862. PubMed ID: 36332787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Momelotinib: an emerging treatment for myelofibrosis patients with anemia.
    Chifotides HT; Bose P; Verstovsek S
    J Hematol Oncol; 2022 Jan; 15(1):7. PubMed ID: 35045875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis.
    Bewersdorf JP; Jaszczur SM; Afifi S; Zhao JC; Zeidan AM
    Cancer Manag Res; 2019; 11():10777-10790. PubMed ID: 31920387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Managing patients with myelofibrosis and thrombocytopenia.
    Yilmaz M; Verstovsek S
    Expert Rev Hematol; 2022 Mar; 15(3):233-241. PubMed ID: 35316110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis.
    Talpaz M; Kiladjian JJ
    Leukemia; 2021 Jan; 35(1):1-17. PubMed ID: 32647323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SOHO State of the Art Updates and Next Questions: Identifying and Treating "Progression" in Myelofibrosis.
    Bose P; Verstovsek S
    Clin Lymphoma Myeloma Leuk; 2021 Oct; 21(10):641-649. PubMed ID: 34272171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SOHO State of the Art Updates and Next Questions: Novel Therapies in Development for Myelofibrosis.
    Chifotides HT; Bose P; Masarova L; Pemmaraju N; Verstovsek S
    Clin Lymphoma Myeloma Leuk; 2022 Apr; 22(4):210-223. PubMed ID: 34840087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.